Managed Care - August 2012 - (Page 6A)

Help adult patients with type 2 diabetes gain greater access Get to know Victoza® on a deeper level. Powerful reductions in A1C from -0.8% to -1.5%* Low rate of hypoglycemia May reduce weight ® Flexible dosing any time of day, independent of meals VictozaCare™ helps patients stay on track with ongoing support —Victoza is not indicated for the management of obesity, and weight change was a secondary end point in clinical trials —Patients enrolled in VictozaCare™ were more adherent to Victoza® than those not enrolled† To see how Victoza® works for your patients, visit VictozaPro.com/GLP1. Indications and usage Victoza® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Because of the uncertain relevance of the rodent thyroid C-cell tumor findings to humans, prescribe Victoza® only to patients for whom the potential benefits are considered to outweigh the potential risk. Victoza® is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise. In clinical trials of Victoza®, there were more cases of pancreatitis with Victoza® than with comparators. Victoza® has not been studied sufficiently in patients with a history of pancreatitis to determine whether these patients are at increased risk for pancreatitis while using Victoza®. Use with caution in patients with a history of pancreatitis. Victoza® is not a substitute for insulin. Victoza® should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. The concurrent use of Victoza and insulin has not been studied. ® calcitonin or thyroid ultrasound will mitigate human risk of thyroid C-cell tumors. Patients should be counseled regarding the risk and symptoms of thyroid tumors. If pancreatitis is suspected, Victoza® should be discontinued. Victoza® should not be re-initiated if pancreatitis is confirmed. When Victoza® is used with an insulin secretagogue (e.g. a sulfonylurea) serious hypoglycemia can occur. Consider lowering the dose of the insulin secretagogue to reduce the risk of hypoglycemia. Renal impairment has been reported postmarketing, usually in association with nausea, vomiting, diarrhea, or dehydration, which may sometimes require hemodialysis. Use caution when initiating or escalating doses of Victoza® in patients with renal impairment. There have been no studies establishing conclusive evidence of macrovascular risk reduction with Victoza® or any other antidiabetic drug. The most common adverse reactions, reported in ≥5% of patients treated with Victoza® and more commonly than in patients treated with placebo, are headache, nausea, diarrhea, and anti-liraglutide antibody formation. Immunogenicity-related events, including urticaria, were more common among Victoza®-treated patients (0.8%) than among comparator-treated patients (0.4%) in clinical trials. Victoza® has not been studied in type 2 diabetes patients below 18 years of age and is not recommended for use in pediatric patients. Victoza® should be used with caution in patients with hepatic impairment. Please see brief summary of Prescribing Information on adjacent page. *Victoza® 1.2 mg and 1.8 mg when used alone or in combination with OADs. † Crossix ScoreBoard™ Report, September 2011. Adherence measured by number of actual Victoza® prescriptions filled for existing Victoza® patients enrolled in VictozaCare™ versus a match-pair control group not enrolled in VictozaCare™ through first 8 months of enrollment. Important safety information Liraglutide causes dose-dependent and treatment-durationdependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Victoza® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be ruled out by clinical or nonclinical studies. Victoza® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Based on the findings in rodents, monitoring with serum calcitonin or thyroid ultrasound was performed during clinical trials, but this may have increased the number of unnecessary thyroid surgeries. It is unknown whether monitoring with serum Victoza® is a registered trademark and VictozaCare™ is a trademark of Novo Nordisk A/S. © 2012 Novo Nordisk 1111-00006045-1 January 2012 http://www.VictozaPro.com/GLP1 http://www.VictozaPro.com/GLP1

Table of Contents for the Digital Edition of Managed Care - August 2012

Managed Care - August 2012
Editor’s Memo
Contents
Legislation & Regulation
News & Commentary
Medication Management
Evidence Review
Compensation Monitor
Private Exchanges: Practice Makes Perfect
Hospitals and Providers Ganging Up on Plans?
Q&A: Kaiser Permanente’s Sharon Levine, MD
God Save the Health Care System!
Future Points to Greater PBM/Plan Cooperation
Formulary Files
Plan Watch
Tomorrow’s Medicine
Outlook

Managed Care - August 2012

https://www.nxtbook.com/nxtbooks/medimedia/managedcare_201601
https://www.nxtbook.com/nxtbooks/medimedia/managedcare_201512
https://www.nxtbook.com/nxtbooks/medimedia/managedcare_201511
https://www.nxtbook.com/nxtbooks/medimedia/managedcare_201510
https://www.nxtbook.com/nxtbooks/medimedia/managedcare_201509
https://www.nxtbook.com/nxtbooks/medimedia/managedcare_201508
https://www.nxtbook.com/nxtbooks/medimedia/managedcare_201507
https://www.nxtbook.com/nxtbooks/medimedia/managedcare_201506
https://www.nxtbook.com/nxtbooks/medimedia/managedcare_201505
https://www.nxtbook.com/nxtbooks/medimedia/managedcare_201504
https://www.nxtbook.com/nxtbooks/medimedia/managedcare_201503
https://www.nxtbook.com/nxtbooks/medimedia/managedcare_201502
https://www.nxtbook.com/nxtbooks/medimedia/managedcare_201501
https://www.nxtbookmedia.com